Journal of Gastrointestinal Cancer

, Volume 44, Issue 3, pp 293–304 | Cite as

Preoperative Platelet Count Associates with Survival and Distant Metastasis in Surgically Resected Colorectal Cancer Patients

  • Shaogui Wan
  • Yinzhi Lai
  • Ronald E. Myers
  • Bingshan Li
  • Terry Hyslop
  • Jack London
  • Devjani Chatterjee
  • Juan P. Palazzo
  • Ashlie L. Burkart
  • Kejin Zhang
  • Jinliang Xing
  • Hushan Yang
Original Research

Abstract

Objective

Platelets have been implicated in cancer metastasis and prognosis. No population-based study has been reported as to whether preoperative platelet count directly predicts metastatic recurrence of colorectal cancer (CRC) patients.

Design

Using a well-characterized cohort of 1,513 surgically resected CRC patients, we assessed the predictive roles of preoperative platelet count in overall survival, overall recurrence, as well as locoregional and distant metastatic recurrences.

Results

Patients with clinically high platelet count (≥400 × 109/L) measured within 1 month before surgery had a significantly unfavorable survival (hazard ratio [HR] = 1.66, 95 % confidence interval [CI] 1.34–2.05, P = 2.6 × 10−6, Plog rank = 1.1 × 10−11) and recurrence (HR = 1.90, 1.24–2.93, P = 0.003, Plog rank = 0.003). The association of platelet count with recurrence was evident only in patients with metastatic (HR = 2.81, 1.67–4.74, P = 1.1 × 10−4, Plog rank = 2.6 × 10−6) but not locoregional recurrence (HR = 0.59, 95 % CI 0.21–1.68, P = 0.325, Plog rank = 0.152). The findings were internally validated through bootstrap resampling (P < 0.01 at 98.6 % of resampling). Consistently, platelet count was significantly higher in deceased than living patients (P < 0.0001) and in patients with metastatic recurrence than locoregional (P = 0.004) or nonrecurrent patients (P < 0.0001). Time-dependent modeling indicated that the increased risks for death and metastasis associated with elevated preoperative platelet counts persisted up to 5 years after surgery.

Conclusion

Our data demonstrated that clinically high level of preoperative platelets was an independent predictor of CRC survival and metastasis. As an important component of the routinely tested complete blood count panel, platelet count may be a cost-effective and noninvasive marker for CRC prognosis and a potential intervention target to prevent metastatic recurrence.

Keywords

Platelet Thrombocytosis CRC Survival Recurrence Metastasis 

Supplementary material

12029_2013_9491_MOESM1_ESM.docx (309 kb)
ESM 1(DOCX 309 kb)

References

  1. 1.
    Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36.PubMedCrossRefGoogle Scholar
  2. 2.
    Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nature reviews. Cancer. 2009;9:489–99.PubMedGoogle Scholar
  3. 3.
    Chau I, Allen MJ, Cunningham D, Norman AR, Brown G, Ford HE, et al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol: official j Am Soc Clin Oncol. 2004;22:1420–9.CrossRefGoogle Scholar
  4. 4.
    Arriola E, Navarro M, Pares D, Munoz M, Pareja L, Figueras J, et al. Imaging techniques contribute to increased surgical rescue of relapse in the follow-up of colorectal cancer. Dis Colon Rectum. 2006;49:478–84.PubMedCrossRefGoogle Scholar
  5. 5.
    Rodriguez-Moranta F, Salo J, Arcusa A, Boadas J, Pinol V, Bessa X, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol: official j Am Soc Clin Oncol. 2006;24:386–93.CrossRefGoogle Scholar
  6. 6.
    Safi F, Beyer HG. The value of follow-up after curative surgery of colorectal carcinoma. Cancer Detect Prev. 1993;17:417–24.PubMedGoogle Scholar
  7. 7.
    Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331:1559–64.PubMedCrossRefGoogle Scholar
  8. 8.
    Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nature reviews. Cancer. 2002;2:563–72.PubMedGoogle Scholar
  9. 9.
    Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature reviews. Cancer. 2003;3:453–8.PubMedGoogle Scholar
  10. 10.
    Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127:679–95.PubMedCrossRefGoogle Scholar
  11. 11.
    Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nature reviews. Cancer. 2009;9:239–52.PubMedGoogle Scholar
  12. 12.
    Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nature reviews. Cancer. 2009;9:274–84.PubMedGoogle Scholar
  13. 13.
    Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol. 2002;3:425–30.PubMedCrossRefGoogle Scholar
  14. 14.
    Gupta GP, Massague J. Platelets and metastasis revisited: a novel fatty link. J Clin Invest. 2004;114:1691–3.PubMedGoogle Scholar
  15. 15.
    Erpenbeck L, Schon MP. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood. 2010;115:3427–36.PubMedCrossRefGoogle Scholar
  16. 16.
    Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nature reviews. Cancer. 2011;11:123–34.Google Scholar
  17. 17.
    Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9:237–49.PubMedCrossRefGoogle Scholar
  18. 18.
    Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial–mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20:576–90.PubMedCrossRefGoogle Scholar
  19. 19.
    Monreal M, Fernandez-Llamazares J, Pinol M, Julian JF, Broggi M, Escola D, et al. Platelet count and survival in patients with colorectal cancer—a preliminary study. Thromb Haemost. 1998;79:916–8.PubMedGoogle Scholar
  20. 20.
    Sasaki K, Kawai K, Tsuno NH, Sunami E, Kitayama J. Impact of preoperative thrombocytosis on the survival of patients with primary colorectal cancer. World J Surg. 2011;36:192–200.CrossRefGoogle Scholar
  21. 21.
    Symbas NP, Townsend MF, El-Galley R, Keane TE, Graham SD, Petros JA. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int. 2000;86:203–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366:610–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Gucer F, Moser F, Tamussino K, Reich O, Haas J, Arikan G, et al. Thrombocytosis as a prognostic factor in endometrial carcinoma. Gynecol Oncol. 1998;70:210–4.PubMedCrossRefGoogle Scholar
  24. 24.
    Lopes A, Daras V, Cross PA, Robertson G, Beynon G, Monaghan JM. Thrombocytosis as a prognostic factor in women with cervical cancer. Cancer. 1994;74:90–2.PubMedCrossRefGoogle Scholar
  25. 25.
    Sagman U, Maki E, Evans WK, Warr D, Shepherd FA, Sculier JP, et al. Small-cell carcinoma of the lung: derivation of a prognostic staging system. J Clin Oncol: official j Am Soc Clin Oncol. 1991;9:1639–49.Google Scholar
  26. 26.
    Pedersen LM, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. EurRespir j:official J Eur Soc Clin Respir. 1996;9:1826–30.CrossRefGoogle Scholar
  27. 27.
    Henderson AR. The bootstrap: a technique for data-driven statistics. Using computer-intensive analyses to explore experimental data. Clin Chim Acta Int J Clin Chem. 2005;359:1–26.CrossRefGoogle Scholar
  28. 28.
    Kaushansky K. Historical review: megakaryopoiesis and thrombopoiesis. Blood. 2008;111:981–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Schafer AI. Thrombocytosis. N Engl J Med. 2004;350:1211–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Royston P. A strategy for modelling the effect of a continuous covariate in medicine and epidemiology. Stat Med. 2000;19:1831–47.PubMedCrossRefGoogle Scholar
  31. 31.
    Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482–94.PubMedCrossRefGoogle Scholar
  32. 32.
    Skoda RC. Thrombocytosis. Hematology Am Soc Hematol Educ Program 2009:159–67.Google Scholar
  33. 33.
    O'Keefe SC, Marshall FF, Issa MM, Harmon MP, Petros JA. Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy. J Urol. 2002;168:1378–80.PubMedCrossRefGoogle Scholar
  34. 34.
    Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105:178–85.PubMedCrossRefGoogle Scholar
  35. 35.
    Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999;59:1295–300.PubMedGoogle Scholar
  36. 36.
    Mohle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A. 1997;94:663–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell. 2006;10:355–62.PubMedCrossRefGoogle Scholar
  38. 38.
    Boucharaba A, Serre CM, Gres S, Saulnier-Blache JS, Bordet JC, Guglielmi J, et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest. 2004;114:1714–25.PubMedGoogle Scholar
  39. 39.
    Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275–92.PubMedCrossRefGoogle Scholar
  40. 40.
    Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med. 1999;245:295–300.PubMedCrossRefGoogle Scholar
  41. 41.
    Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost. 2004;30:95–108.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Shaogui Wan
    • 1
  • Yinzhi Lai
    • 1
  • Ronald E. Myers
    • 1
  • Bingshan Li
    • 2
  • Terry Hyslop
    • 3
  • Jack London
    • 4
  • Devjani Chatterjee
    • 4
  • Juan P. Palazzo
    • 5
  • Ashlie L. Burkart
    • 5
  • Kejin Zhang
    • 1
  • Jinliang Xing
    • 6
  • Hushan Yang
    • 1
  1. 1.Division of Population Science, Department of Medical Oncology, Kimmel Cancer CenterThomas Jefferson UniversityPhiladelphiaUSA
  2. 2.Center for Human Genetics Research, Department of Molecular Physiology and BiophysicsVanderbilt UniversityNashvilleUSA
  3. 3.Division of Biostatistics, Department of Pharmacology and Experimental TherapeuticsThomas Jefferson UniversityPhiladelphiaUSA
  4. 4.Department of Cancer BiologyThomas Jefferson UniversityPhiladelphiaUSA
  5. 5.Department of PathologyThomas Jefferson UniversityPhiladelphiaUSA
  6. 6.Department of Cell BiologyFourth Military Medical UniversityXi’anChina

Personalised recommendations